SYDNEY, AUSTRALIA – 02 November 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapiesfor cancer and autoimmune disease, today announced that Marc Voigt, CEO will be presenting at two upcoming investor conferences:
Event: Bell Potter Healthcare Conference 2022
Date: Wednesday, 9 November 2022
Time: 10:00am – 10:30am (AEDT)
Event: 13th Annual Jefferies London Healthcare Conference
Date: Thursday, 17 November 2022
Time: 1:30pm – 2pm (UTC)
For more information, download the attached PDF.
Download this document
